Owens Thomas W, Gilmore Andrew P, Streuli Charles H, Foster Fiona M
Wellcome Trust Centre for Cell Matrix Research, Faculty of Life Sciences, University of Manchester, Manchester, M13 9PT, UK ; Department of Physiology, Sydney Medical School & Bosch Institute, the University of Sydney, NSW, Australia.
Wellcome Trust Centre for Cell Matrix Research, Faculty of Life Sciences, University of Manchester, Manchester, M13 9PT, UK.
J Carcinog Mutagen. 2013 May 27;Suppl 14. doi: 10.4172/2157-2518.S14-004.
Cancer is a disease in which normal physiological processes are imbalanced, leading to tumour formation, metastasis and eventually death. Recent biological advances have led to the advent of targeted therapies to complement traditional chemotherapy and radiotherapy. However, a major problem still facing modern medicine is resistance to therapies, whether targeted or traditional. Therefore, to increase the survival rates of cancer patients, it is critical that we continue to identify molecular targets for therapeutic intervention. The Inhibitor of Apoptosis (IAP) proteins act downstream of a broad range of stimuli, such as cytokines and extracellular matrix interactions, to regulate cell survival, proliferation and migration. These processes are dysregulated during tumourigenesis and are critical to the metastatic spread of the disease. IAPs are commonly upregulated in cancer and have therefore become the focus of much research as both biomarkers and therapeutic targets. Here we discuss the roles that IAPs may play in cancer, and the potential benefits and pitfalls that targeting IAPs could have in the clinic.
癌症是一种正常生理过程失衡的疾病，会导致肿瘤形成、转移并最终导致死亡。最近的生物学进展催生了靶向疗法，以补充传统的化疗和放疗。然而，现代医学仍然面临的一个主要问题是对疗法的耐药性，无论是靶向疗法还是传统疗法。因此，为了提高癌症患者的生存率，继续确定治疗干预的分子靶点至关重要。凋亡抑制蛋白（IAP）在多种刺激（如细胞因子和细胞外基质相互作用）的下游发挥作用，以调节细胞存活、增殖和迁移。这些过程在肿瘤发生过程中失调，并且对疾病的转移扩散至关重要。IAP在癌症中通常上调，因此作为生物标志物和治疗靶点已成为许多研究的焦点。在这里，我们讨论IAP在癌症中可能发挥的作用，以及靶向IAP在临床中可能带来的潜在益处和风险。
